Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $9.5714.

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and set a $12.00 price target on shares of Biomea Fusion in a research note on Wednesday, March 25th. Rodman & Renshaw initiated coverage on Biomea Fusion in a report on Tuesday, January 13th. They issued a “buy” rating and a $8.00 price objective for the company. Citigroup boosted their price objective on Biomea Fusion from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, March 27th. Finally, Wall Street Zen raised shares of Biomea Fusion from a “sell” rating to a “hold” rating in a report on Saturday, March 28th.

Biomea Fusion Stock Performance

Biomea Fusion stock opened at $1.54 on Monday. Biomea Fusion has a 12 month low of $0.87 and a 12 month high of $3.08. The business’s 50 day simple moving average is $1.30 and its 200 day simple moving average is $1.40. The company has a market cap of $111.34 million, a price-to-earnings ratio of -1.18 and a beta of -0.25.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Scientech Research LLC purchased a new position in Biomea Fusion during the 3rd quarter valued at about $25,000. Engineers Gate Manager LP purchased a new stake in shares of Biomea Fusion in the second quarter worth about $26,000. Millennium Management LLC boosted its position in shares of Biomea Fusion by 156.7% in the fourth quarter. Millennium Management LLC now owns 25,677 shares of the company’s stock valued at $32,000 after acquiring an additional 15,675 shares during the period. Vanguard Personalized Indexing Management LLC bought a new position in shares of Biomea Fusion in the third quarter valued at approximately $32,000. Finally, Virtu Financial LLC purchased a new position in Biomea Fusion during the third quarter valued at approximately $39,000. Institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.